Ventrus Biosciences Inc. (NASDAQ:VTUS) has been bleeding red at the stock markets ever since the company reported that its phase three clinical trial of its target drug Diltiazem had turned out to be disappointing, since the data showed no appreciable improvement in the recovery rate of the trail subjects. Ventrus Biosciences Inc. (NASDAQ:VTUS) shares after opening at $1.25 moved to $1.28 on last trade day and at the end of the day closed at $1.19. Company price to cash ratio as 0.77. Ventrus Biosciences Inc. (NASDAQ:VTUS) showed a negative weekly performance of -13.77%.
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Year ended December 31, 2013 compared to year ended December 31, 2012 Net revenues. Net revenues in 2013 decreased approximately $16.8 million compared to 2012. Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) shares fell -0.89% in last trading session and ended the day on $4.46. CPIX return on equity ratio is recorded as -2.60% and its return on assets is -2.30%. Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) yearly performance is -12.38%.
On March 26, 2014, Ruthigen, Inc. (NASDAQ:RTGN) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of its securities. Ruthigen Inc. (NASDAQ:RTGN) shares moved down -1.32% in last trading session and was closed at $6.75, while trading in range of $6.51 – $6.85. Ruthigen Inc. (NASDAQ:RTGN) year to date (YTD) performance is -6.90%.
Recro Pharma Inc. (NASDAQ:REPH) after its first few weeks of public trading has posted 21 percent depreciation in its market value. Recro Pharma Inc. (NASDAQ:REPH) weekly performance is -14.88%. On last trading day company shares ended up $6.98. Recro Pharma Inc. (NASDAQ:REPH) distance from 50-day simple moving average (SMA50) is -13.72%. Analysts mean target price for the company is $26.00.